Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics

• Status: Unknown status
• Trial end date: 2020-12-01

Summary

Major Depressive Disorder is one of the most common mental diseases,which increases health-care costs and the financial burden to families and societies. Considering its complex clinical symptoms and diversity of comorbidity, depressive disorder's recognition，diagnosis，and antihistone are based on symptomatology,which is lack of multidimensional diagnosis technique based on clinical pathological characteristics,as well as lack of individualized therapy strategy based on quantified evaluation. Besides, other physical diseases，such as nervous system diseases, cardiovascular diseases，endocrine diseases, have the high comorbidity of depressive disorder. However，there is no precise diagnosis technique or standardized therapy strategy. With all those taken into consideration,our study is aimed to adopt E-mental health and m-Health to explore multi-dimensional diagnosis, individualized therapy and management technique based on molecular biology,nerve electrophysiology，and neuroimaging technology etc.

• Phase: Phase 4

Details

• Lead Sponsor: Shanghai Mental Health Center
• Collaborators: Air Force Military Medical University, China; Central South University; Chinese Academy of Sciences; Corning Hospital, Shenzhen City; First Affiliated Hospital Xi'an Jiaotong University; Fourth Military Medical University; Hangzhou Seventh People's Hospital; Peking University Sixth Hospital; Renmin Hospital of Wuhan University; Second Military Medical University; Seventh People's Hospital of Hangzhou; Shandong Mental Health Center; Shanghai Jiao Tong University School of Medicine; Shanxi Medical University; The First Affiliated Hospital of Kunming Medical College; the First Specialized Subject Hospital of Harbin; Wuhan Mental Health Center; Wuhan Mental Health Centre; Zhejiang University
• Treatments: Bupropion; Fluoxetine; Fluvoxamine; Lithium Carbonate; Mianserin; Mirtazapine; Serotonin and Noradrenaline Reuptake Inhibitors